Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
PLoS Genet ; 6(6): e1000985, 2010 Jun 10.
Artigo em Inglês | MEDLINE | ID: mdl-20548961

RESUMO

Protein palmitoylation has emerged as an important mechanism for regulating protein trafficking, stability, and protein-protein interactions; however, its relevance to disease processes is not clear. Using a genome-wide, phenotype driven N-ethyl-N-nitrosourea-mediated mutagenesis screen, we identified mice with failure to thrive, shortened life span, skin and hair abnormalities including alopecia, severe osteoporosis, and systemic amyloidosis (both AA and AL amyloids depositions). Whole-genome homozygosity mapping with 295 SNP markers and fine mapping with an additional 50 SNPs localized the disease gene to chromosome 7 between 53.9 and 56.3 Mb. A nonsense mutation (c.1273A>T) was located in exon 12 of the Zdhhc13 gene (Zinc finger, DHHC domain containing 13), a gene coding for palmitoyl transferase. The mutation predicted a truncated protein (R425X), and real-time PCR showed markedly reduced Zdhhc13 mRNA. A second gene trap allele of Zdhhc13 has the same phenotypes, suggesting that this is a loss of function allele. This is the first report that palmitoyl transferase deficiency causes a severe phenotype, and it establishes a direct link between protein palmitoylation and regulation of diverse physiologic functions where its absence can result in profound disease pathology. This mouse model can be used to investigate mechanisms where improper palmitoylation leads to disease processes and to understand molecular mechanisms underlying human alopecia, osteoporosis, and amyloidosis and many other neurodegenerative diseases caused by protein misfolding and amyloidosis.


Assuntos
Aciltransferases/genética , Alopecia/genética , Amiloidose/genética , Mutação , Osteoporose/genética , Aciltransferases/metabolismo , Envelhecimento , Alopecia/metabolismo , Alopecia/patologia , Amiloidose/metabolismo , Amiloidose/patologia , Animais , Sequência de Bases , Regulação da Expressão Gênica , Imuno-Histoquímica , Camundongos , Especificidade de Órgãos , Osteoporose/metabolismo , Osteoporose/patologia , Fenótipo
2.
Pharmacogenomics ; 10(12): 1905-13, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19958090

RESUMO

UNLABELLED: Warfarin, a widely prescribed oral anticoagulant, is used for the prevention of thromboembolism. Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements. However, it is likely that other genes could also affect warfarin dose. AIMS: In this study, we aimed to identify additional genes influencing warfarin dosing in the Han-Chinese population. MATERIALS & METHODS: In this study, we screened for SNPs in 13 genes (VKORC1, CYP2C9, CYP2C18, PROC, APOE, EPHX1, CALU, GGCX, ORM1, ORM2, factor II, factor VII and CYP4F2) and tested their associations with warfarin dosing with univariate and multiple regression analysis. RESULTS: Polymorphisms in the VKORC1 gene have the strongest effects on warfarin dose, followed by CYP2C9*3. In addition, our results showed that CYP2C18, PROC and EPHX1 have small but significant associations with warfarin dose. In multiple regression analysis, PROC and EPHX1 explained 3% of the dose variation. The incorporation of these two genes into warfarin dosing algorithms could improve the accuracy of prediction in the Han-Chinese population.


Assuntos
Anticoagulantes/administração & dosagem , Hidrocarboneto de Aril Hidroxilases/genética , Povo Asiático/genética , Oxigenases de Função Mista/genética , Polimorfismo de Nucleotídeo Único , Varfarina/administração & dosagem , Anticoagulantes/farmacocinética , Anticoagulantes/uso terapêutico , Citocromo P-450 CYP2C19 , Relação Dose-Resposta a Droga , Feminino , Frequência do Gene , Genótipo , Humanos , Modelos Lineares , Masculino , Taxa de Depuração Metabólica/genética , Pessoa de Meia-Idade , Taiwan , Vitamina K Epóxido Redutases , Varfarina/farmacocinética , Varfarina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa